^
Association details:
| Biomarker: | CD52 expression |
|---|---|
| Cancer: | Prolymphocytic Leukemia |
| Drug: | Campath (alemtuzumab) (CD52 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/05/2023
Excerpt:
T-Cell Prolymphocytic Leukemia….Retreatment with alemtuzumab (IV) ± pentostatin (if CD52 expression is still positive and relapse after a period of remission following first-line therapy).
Secondary therapy:
pentostatin
